Vimarsana
Biggest News Aggregation in the World

Page 6 - Dose Escalation News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Dose Escalation. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Dose Escalation Today - Breaking & Trending Today

AbbVie Presents Data at the 64th American Society of Hematology (ASH) Annual Meeting Evaluating Epcoritamab (DuoBody®-CD3xCD20) Across B-Cell Lymphomas - Vimarsana News

AbbVie Presents Data at the 64th American Society of Hematology (ASH) Annual Meeting Evaluating Epcoritamab (DuoBody®-CD3xCD20) Across B-Cell Lymphomas

/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced data from multiple clinical trials evaluating epcoritamab (DuoBody®-CD3xCD20), an investigational...

Adagene Announces Poster Presentations on Anti-CTLA-4 NEObody, ADG116, at Upcoming Society for Immunotherapy of Cancer's (SITC) Annual Meeting in November Seite 1 - Vimarsana News

Adagene Announces Poster Presentations on Anti-CTLA-4 NEObody, ADG116, at Upcoming Society for Immunotherapy of Cancer's (SITC) Annual Meeting in November Seite 1

11.10.2022 - - NEObody technology platform enables dynamic targeting of a distinct epitope of CTLA-4 for enhanced safety and efficacy -        - Data from phase 1b/2 studies in heavily pre-treated patients showcase differentiated safety profile of ... Seite 1

Premas Biotech reports positive preliminary Phase-1 data for its oral Covid-19 vaccine, developed for Oravax Medical - Vimarsana News

Premas Biotech reports positive preliminary Phase-1 data for its oral Covid-19 vaccine, developed for Oravax Medical

Gurugram (Haryana) [India], October 8 (ANI/PRNewswire): Premas Biotech, developer of technologies & bioprocesses for novel proteins, today announced that Oravax Medical Inc., a US-based company that Premas Biotech is a shareholder in, reported positive preliminary data from its Phase 1 trial in South Africa of an oral Covid-19 vaccine candidate. Preliminary Phase 1 trial results from the first cohort include: - Significant antibody response (2-6 fold over baseline) as measured by multiple markers of immune response to VLP vaccine antigens observed in the majority of the patients dosed - wa...

Byondis Initiates Phase I Study of Next Generation Antibody-Drug Conjugate BYON3521 - Vimarsana News

Byondis Initiates Phase I Study of Next Generation Antibody-Drug Conjugate BYON3521

Byondis Initiates Phase I Study of Next Generation Antibody-Drug Conjugate BYON3521 ·        BYON3521 Targets c-MET, Widely Overexpressed in Solid Tumors·        Therapy Uses Proprietary Technologies Designed to Enhance Efficacy...

Byondis B.V.: Byondis Initiates Phase I Study of Next Generation Antibody-Drug Conjugate BYON3521 - Vimarsana News

Byondis B.V.: Byondis Initiates Phase I Study of Next Generation Antibody-Drug Conjugate BYON3521

BYON3521 Targets c-MET, Widely Overexpressed in Solid TumorsTherapy Uses Proprietary Technologies Designed to Enhance Efficacy and SafetyNIJMEGEN, Netherlands, Aug. 25, 2022 /PRNewswire/ --